{
    "Trade/Device Name(s)": [
        "Access PCT",
        "Access PCT Reagent"
    ],
    "Submitter Information": "Beckman Coulter, Inc.",
    "510(k) Number": "K222996",
    "Predicate Device Reference 510(k) Number(s)": [
        "K192271"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PTF"
    ],
    "Summary Letter Date": "September 27, 2022",
    "Summary Letter Received Date": "September 28, 2022",
    "Submission Date": "February 17, 2023",
    "Regulation Number(s)": [
        "21 CFR 866.3215"
    ],
    "Regulation Name(s)": [
        "Device To Detect And Measure Non-Microbial Analyte(s) In Human Clinical Specimens To Aid In Assessment Of Patients With Suspected Sepsis"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "immunology"
    ],
    "Analyte(s)": [
        "Procalcitonin (PCT)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (Lithium heparin)",
        "Plasma (EDTA)"
    ],
    "Specimen Container(s)": [
        "Lithium heparin tube",
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Access Immunoassay Systems",
        "DxI 9000 Access Immunoassay Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Paramagnetic particle chemiluminescent immunoassay",
        "Two-step sandwich immunoassay",
        "Automated immunoassay"
    ],
    "Methodologies": [
        "Chemiluminescent immunoassay",
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Beckman Coulter Access PCT paramagnetic chemiluminescent immunoassay for quantitative procalcitonin measurement in serum and plasma",
    "Indications for Use Summary": "Aids in risk assessment of critically ill ICU patients for progression to severe sepsis and septic shock via quantitative measurement of procalcitonin in serum and plasma using the Access Immunoassay Systems",
    "fda_folder": "Microbiology"
}